Université libre de Bruxelles

About: Université libre de Bruxelles is a education organization based out in Brussels, Belgium. It is known for research contribution in the topics: Population & Breast cancer. The organization has 24974 authors who have published 56969 publications receiving 2084303 citations. The organization is also known as: ULB.

Skyrme-Hartree-Fock-Bogoliubov nuclear mass formulas: crossing the 0.6 MeV accuracy threshold with microscopically deduced pairing.

Abstract: We present a new Skyrme-Hartree-Fock-Bogoliubov nuclear-mass model in which the contact-pairing force is constructed from microscopic pairing gaps of symmetric nuclear matter and neutron matter calculated from realistic two- and three-body forces, with medium-polarization effects included. With the pairing being treated more realistically than in any of our earlier models, the rms deviation with respect to essentially all the available mass data falls to 0.581 MeV, the best value ever found within the mean-field framework. Since our Skyrme force is also constrained by the properties of pure neutron matter, this new model is particularly well suited for application to astrophysical problems involving a neutron-rich environment, such as the elucidation of the r process of nucleosynthesis, and the description of supernova cores and neutron-star crusts.

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

Abstract: OBJECTIVE: Major depressive disorder has been linked with inflammatory processes, but it is unclear whether individual differences in levels of inflammatory biomarkers could help match patients to treatments that are most likely to be beneficial. The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). METHOD: The hypothesis was tested in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, a multicenter open-label randomized clinical trial. CRP was measured with a high-sensitivity method in serum samples from 241 adult men and women with major depressive disorder randomly allocated to 12-week treatment with escitalopram (N=115) or nortriptyline (N=126). The primary outcome measure was the score on the Montgomery-Asberg Depression Rating Scale (MADRS), administered weekly. RESULTS: CRP level at baseline differentially predicted treatment outcome with the two antidepressants (CRP-drug interaction: β=3.27, 95% CI=1.65, 4.89). For patients with low levels of CRP (<1 mg/L), improvement on the MADRS score was 3 points higher with escitalopram than with nortriptyline. For patients with higher CRP levels, improvement on the MADRS score was 3 points higher with nortriptyline than with escitalopram. CRP and its interaction with medication explained more than 10% of individual-level variance in treatment outcome. CONCLUSIONS: An easily accessible peripheral blood biomarker may contribute to improvement in outcomes of major depressive disorder by personalizing treatment choice.

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

Abstract: Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Abstract: PurposeStudies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC.Patients and MethodsTumors were tested for AR with an immunohistochemistry assay optimized for breast cancer; nuclear AR staining > 0% was considered positive. Patients received enzalutamide 160 mg once per day until disease progression. The primary end point was clinical benefit rate (CBR) at 16 weeks. Secondary end points included CBR at 24 weeks, progression-free survival, and safety. End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup).ResultsOf 118 patients enrolled, 78 were evaluable. CBR at 16 weeks was 25% (95% CI, 17% to 3...

Pulmonary emphysema: objective quantification at multi-detector row CT--comparison with macroscopic and microscopic morphometry.

Abstract: Purpose: To prospectively compare pulmonary function tests and helical computed tomographic (CT) indexes for quantifying pulmonary emphysema with macroscopic and microscopic morphometry. Materials and Methods: The investigation was approved by the local ethics committee, and written informed consent was obtained from patients. Multi–detector row CT of the thorax was performed with simultaneous acquisition of four 1-mm sections in 80 patients (57 men, 23 women; age range, 38–79 years) referred for surgical resection of lung cancer. From the raw data, 1.25-mm-thick sections were reconstructed at 10-mm intervals. Relative areas of lung with attenuation coefficients lower than nine thresholds and eight percentiles of the distribution of attenuation coefficients were calculated. Relative areas and percentiles were compared with areas found macroscopically to have emphysema and with two microscopic indexes assessed on resected specimens. Pulmonary function tests were measured 24–48 hours before surgery. Spearma...